SCHEMBL2280462

SCHEMBL2280462

CCOC(=O)Cc1cccc(Oc2ccc(Br)cc2CSc2ccc3ccccc3n2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.49
PRNP P04156 4/20 0.49
MEN1 O00255 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.41
ALDH1A1 P00352 1/20 0.41
F10 P00742 1/20 0.39
ALOX5 P09917 1/20 0.39
MAPT P10636 4/20 0.38
CYSLTR2 Q9NS75 2/20 0.38
CYSLTR1 Q9Y271 2/20 0.38
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
PKM P14618 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2278000 0.89 PRNP (0.43) KMT2APRNPMEN1ALOX5MAPT
SCHEMBL2278029 0.85 ALDH1A1 (0.48) KMT2AMEN1L3MBTL1ALDH1A1F10
SCHEMBL2278254 0.84 PPARG (0.48) L3MBTL1ALDH1A1F10MAPTPPARG
SCHEMBL2278370 0.81 F10 (0.42) KMT2AMEN1L3MBTL1F10PPARG
SCHEMBL2282521 0.79 F10 (0.39) KMT2AMEN1F10PPARGPPARA
SCHEMBL2281898 0.79 F10 (0.39) KMT2AMEN1ALDH1A1F10MAPT
SCHEMBL2278795 0.79 MAPT (0.47) KMT2AMEN1ALDH1A1F10MAPT
SCHEMBL1644135 0.79 F10 (0.44) KMT2AMEN1L3MBTL1ALDH1A1F10
SCHEMBL1644681 0.79 F10 (0.44) KMT2AMEN1L3MBTL1F10MAPT
SCHEMBL2283387 0.78 F10 (0.40) KMT2AMEN1ALDH1A1F10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US disclosed
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US disclosed
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US disclosed
WO-2010003127-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors PTGDR, PTGDR2, PTGER2 KMT2A 4618/4885PRNP 2091/4885MEN1 4760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.